Navigation Links
Halozyme Reports First Quarter 2013 Financial Results
Date:5/8/2013

received FDA clearance to start an artificial pancreas investigator initiated trial that incorporates Hylenex.  The study will test the effect of Hylenex in the continuous loop setting.
  • Initiated an additional multi-lot campaign with our higher productivity manufacturing process to support potential Roche product launches.
  • Appointed Matt Posard , Senior Vice President and General Manager of Translational & Consumer Genomics at Illumina, Inc., to our Board of Directors.
  • First Quarter 2013 Financial Highlights

  • Revenues for the first quarter of 2013 were $11.8 million, compared to $7.4 million for the first quarter of 2012. Revenues in the first quarter of 2013 included $9.7 million in revenue from research and development reimbursements from partners primarily related to manufacturing activities to support potential launches by our partners.
  • Research and development expenses for the first quarter of 2013 were $22.0 million, compared with $15.9 million for the first quarter of 2012. The increase was due primarily to an increase in manufacturing activities to support potential launches by our partners and an increase in clinical trial activities.
  • Selling, general and administrative expenses for the first quarter of 2013 were $7.6 million, compared to $6.6 million for the first quarter of 2012. The increase was mainly due to an increase in marketing activities.
  • The net loss for the first quarter of 2013 was $19.3 million, or $0.17 per share, compared with a net loss for the first quarter of 2012 of $15.1 million, or $0.14 per share.
  • Cash, cash equivalents and marketable securities were $87.4 million at March 31, 2013, compared with $99.5 million at December 31, 2012. Net cash used in the first quarter of 2013 was approximately $12.0 million.
  • Conference
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. Halozyme Reports First Quarter 2012 Financial Results
    3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    4. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    6. Halozyme Reports Second Quarter 2012 Financial Results
    7. Halozyme to Host Third Quarter Financial Results Conference Call
    8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    9. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
    11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... July 29, 2015  Ortho-Clinical Diagnostics, Inc. (OCD) today ... development. The assays address a range of important tests ... cardiac troponin I. The scientific posters will be delivered ... Meeting to be held July 26 - 30 in ... "Ortho Clinical Diagnostics is emerging stronger than ever since ...
    (Date:7/29/2015)... , July 27, 2015 Research and ... of the "Global Neurostimulation Devices Market 2015" ... analysts forecast the global neurostimulation devices market to ... period 2014-2019. The report, Global Neurostimulation ... an in-depth market analysis with inputs from industry ...
    (Date:7/29/2015)... , July 29, 2015 The Judicial ... this week about whether to centralize Inferior vena cava ... competing IVC manufacturer, Cook Medical, have already been centralized ... devices implanted in patients at risk for a pulmonary ... from traveling to the lungs. Claims against Bard and ...
    Breaking Medicine Technology:Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3Global Neurostimulation Devices Market 2015-2019 2IVC filter litigation continues; law firm provides free information to IVC filter patients 2
    ... A new study published online today ... NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab ... treating age-related macular degeneration (AMD). The ... Trials" (CATT) study, a pioneering comparative effectiveness trial made ...
    ... 2011 PharmaNet Development Group, Inc., a leading provider ... and medical device companies, announced today that Valerie Palumbo ... Quality Assurance. "We are very pleased ... President, PharmaNet Development Group. "Valerie brings deep experience in ...
    Cached Medicine Technology:Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 2Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 3Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 4
    (Date:7/29/2015)... New York, NY (PRWEB) , ... July 29, 2015 , ... ... Petitions were approved by USCIS over the past month! I-829 approvals have been granted ... projects in Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the ...
    (Date:7/29/2015)... ... July 29, 2015 , ... Inspired ... Foundation in March, Steven W. Meier M.D., a prominent orthopedic surgeon and regenerative ... patients with demonstrated financial need. , “We are thrilled for this opportunity to ...
    (Date:7/29/2015)... ... July 29, 2015 , ... Employee Fiduciary, LLC announces ... the general contact information, website, types of plans administered, years in business, and credentials ... and have at least one plan with Employee Fiduciary. A search can be done ...
    (Date:7/29/2015)... ... ... TransFlip is an all new dynamic transition pack for FCPX, containing flipping ... are easy to apply and modify for any skill-level user. TransFlip includes custom bounce ... kinetic flipping panel animations are just a few clicks away. , TransFlip contains over ...
    (Date:7/29/2015)... ... July 29, 2015 , ... Toronto native ... late 1970s, Dr. Cottrell has been making predictions about the economy, politics, social ... many of these prognostications. He warns that extreme weather conditions and increased earthquake ...
    Breaking Medicine News(10 mins):Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2
    ... have discovered that activation of a particular brain region ... The results of this Duke University Medical Center study ... of Nature Neuroscience. ,"Although understanding the ... what drives people like Mother Theresa, it may give ...
    ... growing number of youngsters are contracting tuberculosis, especially those in ... excessive weight loss, according to a report. ... in their 20s. ,According to the report ... people contracted tuberculosis in 2006, an average of 115 people ...
    ... how beneficial traits shape up in natural populations,// but one ... costly traits. Two theories have tried to address this challenge ... selection. ,The theory of hitchhiking has indicated ... become frequent in natural populations when they "hitch a ride" ...
    ... that has left its victims stoned. , Federal agents ... producing establishments Wednesday. The raids are the biggest raids to ... than 5000 pounds of pot (marijuana), as well as pot-laced ... According to the pot retailers, which include marijuana medical clinic ...
    ... research that does not bark up the wrong tree. ,According to ... //evidence to back the fact that owning a dog is indeed ... in lower blood pressure and cholesterol, it reduces the occurrence of ... problems. This could be attributed to the positive impact of owning ...
    ... Novartis bagged the contract to make a chemical that ... million contract// was finalised on Wednesday. ,The ... contracts to fight a possible bird-flu outbreak in humans. ... on Wednesday by the U.S. Department of Health and ...
    Cached Medicine News:Health News:Activation of a Particular Brain Region Predicts Altruism: Study 2Health News:More Youngsters Get Tuberculosis 2Health News:The Evolution of Costly Traits 2
    ... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
    ... Modes of Operation: , Standby: All toggle switches ... 60-ms bursts of 50 Hz separated by .75 s; ... pulse/s); single or repeat , Tetanus: 50 Hz ... Single (4 pulses/2 s); repeat (4 pulses/2 s; repeats ...
    ... , Double Burst : 2 60-ms bursts of 50 ... (1 pulse/s) , Tetanus: 50 Hz (50 pulses/s) ... (4 pulses/2 s) , Output Current: Adjustable from 0-70 ... (200-us duration) , Indicators: Battery LED (green) indicates that ...
    Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
    Medicine Products: